Physician

Charles Vincent Kurkul, M.D.

According to 2025 Medicare claims, Charles Kurkul, M.D. (NPI: 1134419682) practices medical oncology in the Dallas-Plano-Irving, TX market, with the plurality of this provider's patient population coming from Denton, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 76201-4315. Kurkul is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Kurkul's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 720 traditional Medicare patients, billed 184,781 HCPCS/CPT codes, and received $2,253,830 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,662 prescription claims across 246 beneficiaries totaling $3,391,323 in drug costs, led by Revlimid (Lenalidomide). Open Payments data shows 101 records totaling $186,256. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $464,038 and ending at $2,253,830. Concurrently, Part D prescription costs have risen steadily, from $60,622 to $3,391,323. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.